Elicio Therapeutics Inc., a clinical-stage biotechnology company, has announced a virtual key opinion leader event scheduled for June 25, 2025, to discuss its lead product candidate, ELI-002. This AMP-powered therapeutic vaccine is designed to address the challenges of immune evasion in the treatment of mutant-KRAS (mKRAS) driven pancreatic ductal adenocarcinoma (PDAC). The event will feature insights from experts, including Darrell Irvine, Ph.D., and Eileen O'Reilly, M.D., and will cover the proprietary lymph node-targeting amphiphile ("AMP") platform that supports Elicio's novel immunotherapy pipeline. ELI-002 is currently undergoing evaluation in a randomized Phase 2 trial for the adjuvant treatment of mKRAS-driven PDAC. An interim analysis of the study focused on event-driven disease-free survival is anticipated in the third quarter of 2025. A live Q&A session will follow the presentations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.